Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022 for #SLE Belimumab ~ 600% increase!! @RheumNow #ACR24 abst#1259 https://t.co/norl1xk2KF

• https://x.com/bella_mehta/status/1858205209165541866/photo/1

#SLE treatments #ACR24: Compared efficacy & safety of belimumab vs. telitacicept (targets B-lymphocyte stimulator (BLyS) and proliferation-inducing ligand(APRIL)) Both improved disease activity with no difference in efficacy Belimumab had lower infection rates @RheumNow abst1544

More data from PAISLEY, deucravacitinib in SLE Small but significant benefit w/respect to joints, a little disappointing tbh Would like to see this for all manifestations ie pericarditis, pleuritis, etc Anyone have an infographic or useful chart? #ACR20 @RheumNow Abstr#1552 https://t.co/tXUoUtssxo

• https://x.com/EBRheum/status/1858206970785706213/photo/1
• https://x.com/EBRheum/status/1858206970785706213/photo/1

Alright help me out here; this is pretty implausible, right? Why would be pts be 11% more adherent to UPA? What's the bio-plausibility here? UPA 10% better than other JAKs? Could do a network meta analysis; betting this doens't replicate #ACR24 @RheumNow Abstr#1362 https://t.co/vpPq3vu9Wf

• https://x.com/EBRheum/status/1858196904494186816/photo/1
• https://x.com/EBRheum/status/1858196904494186816/photo/1

Gonzalez Molina et al. MANHATTAN observational study. In PsA after 1st TNFi failure should we use guselkumab or 2nd TNFi? Guselkumab slightly better persistence, DAPSA, and improvements in joint counts. @RheumNow #ACR24 Abstr#1469 https://t.co/X3TMCVys6B https://t.co/vvkUYbzVDq

• Manhattan Study: Observational, Ambispective Study to Describe Persistence and …
• https://x.com/RichardPAConway/status/1858194388360282291/photo/1

TYK2/JAK1 in Dermato? Interesting pre-clinical study of brepocitinib... but we really just need clinical data Glad to see this is headed straight to a Phase 3! Hoping they allow IVIG: has been a problem with many/most/all? recent dermato studies #ACR24 @RheumNow Abstr#0882 https://t.co/KS8fTMBpPR

• https://x.com/EBRheum/status/1858187090082800118/photo/1

In this large 🇦🇺 RA cohort, median time on treatment for upadacitinib was lot higher than other JAKi (28mo vs 17mo) Why? Patient selection, or a real difference between JAKi? Would really like more comparative effectiveness data between JAKi #ACR24 OPAL group ABST1370 @RheumNow https://t.co/OU2ayzqIc8

• https://x.com/drdavidliew/status/1858188438056653021/photo/1

Zhou et al. Phase 2 RCT of XKH004, IL17A/Fi in AxSpA. ASAS40 50.4% vs 25%. Slightly odd dose response variation, but maybe just noise. @RheumNow #ACR24 Abstr#1453 https://t.co/SsTSThFzro https://t.co/C9yK2G4tqB

• Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal…
• https://x.com/RichardPAConway/status/1858185580116328614/photo/1

Getting more data on using deucravacitinib for PsO/PsA manifestations Impressive effect on scalp psoriasis (which often means a lot to patients) Given how safe it is, it's increasingly tempting to use more of it in mild-mod PsA #ACR24 PSORIATYK SCALP trial ABST1137 @RheumNow https://t.co/vxS3RSlIN0

• https://x.com/drdavidliew/status/1858185727491919901/photo/1

Abst #1473 evaluated association of SJC in PROs from 2 Bimekizumab trials (bDMARD naïve vs TNFi-IR) -bDMARD naïve had less SJC at baseline -In both groups, pts w lower SJC had sustained improvement in pain and fatigue over time. #ACR24 @RheumNow https://t.co/zwxsSbga7c

• https://x.com/AdelaCastro222/status/1858180798488424715/photo/1